Stocktoria
Monopar Therapeutics MNPR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-12-19
Monopar Therapeutics statistics & valuation
Market cap$587.4M
P / B4.3×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2025 | FY2025 | FY2025 | FY2024 |
|---|---|---|---|---|---|
| Return on assets | -9.7% | — | — | — | -25.9% |
| Return on equity | -10.0% | — | — | — | -28.3% |
| Current ratio | 51.35 | 56.10 | 33.94 | — | 11.47 |
Source: SEC EDGAR filings · CIK 0001645469 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.